Background: Continuous femoral 3-in-1 block alone is insufficient for the treatment of severe pain after total knee replacement (TKR). Intrathecal (IT) morphine provides effective postoperative analgesia but may result in many side effects. The optimal dose of spinal morphine when combined with continuous 3-in-1 block after TKR is not known.
INTRODUCTION
Total knee replacement (TKR) is associated with marked and prolonged postoperative pain. In fact, TKR is a more painful procedure than total hip replacement and posterolateral lumbar spinal fusion [1] [2] [3] . Achieving adequate analgesia remains a clinical challenge. After TKR, postoperative pain relief can be achieved by several approaches, such as IV patient-controlled analgesia (PCA), epidural analgesia, and femoral 3-in-1 nerve block [4, 5] . Epidural infusions containing local anesthetics (with or without an opioid) provide superior analgesia, but are associated with arterial hypotension, urinary retention, and difficulty with ambulation because of bilateral motor block [5] . In addition, epidural catheterization in the presence of thromboprophylaxis increases the risk of neuraxial hematoma [6] .
Continuous 3-in-1 block is as efficient as epidural analgesia and induces fewer side effects, and is therefore, the preferred technique [5] . However, the pain in the back of the knee after TKR was not relieved by 3-in-1 block [7] . This suggests that both the obturator and the sciatic nerve also provide a major contribution to the innervation of the knee joint [8, 9] .
Although speculative, intrathecal (IT) morphine use will simultaneously provide analgesia for the sciatic nerve distribution and maintain an acceptable level of side effects. A single small dose of IT morphine would be coupled with the femoral nerve block as part of a multimodal analgesia in TKR.
Recently, the authors [10] determined that the addition of a smaller dose, 0.1 mg, of IT morphine to continuous 3-in-1 67.4 ± 7.0 0/20 63.5 ± 10.9 149.8 ± 6.4
92.5 ± 18.6 156. 3 ± 30.8 All values except gender ratio are expressed as mean ± SD. IT: intrathecal. block improves postoperative analgesia compared with 3-in-1 block alone after TKR. We assumed that if combined with 3-in-1 block, the effective dose of IT morphine could be reduced to a smaller one than those speculated by Tarkkila et al (0.3 mg) [11] and Rathmell et al (0.2 mg) [2] . However, the optimal dose and adverse effects of spinal morphine when combined with continuous 3-in-1 block after TKR is not known. Furthermore, previous dose-ranging studies with IT morphine have been performed in hip arthroplasty [12, 13] or combining TKR and open ligament surgery [11] or combining hip and knee arthroplasty [14] , but not performed in only TKR. Rathmell et al [2] suggested that pain after knee arthroplasty was more intense than that after hip arthroplasty. Thus, the practice of combining TKR and other types of major joint surgery in the evaluation of an outcome is not valid as in the study of Tarkkila et al [11] and Jacobson et al [14] .
IT morphine is an effective, convenient, and simple method for management of postoperative pain but may result in many side effects, including postoperative nausea and vomiting (PONV), pruritus, and notably delayed respiratory depression [14] [15] [16] [17] . Furthermore, older patients may be particularly sensitive to the respiratory-depressant effects of IT morphine [18] .
The patients in previous studies had a mean age of 65 [2] , 66 [11] , and 67 year [10] in major knee surgery. Therefore, a minimum effective dose of IT morphine for TKR while avoiding respiratory depression is needed.
We hypothesized that the analgesic dose and side effects of IT morphine when combined with 3-in-1 block might be further reduced than those seen in previous studies [2, 11] .
Accordingly, we performed a trial to establish a minimum effective dose of IT morphine after doses of 0.0, 0.05, 0.1, 0.15, and 0.2 mg and to evaluate side effects when combined with continuous 3-in-1 block after unilateral TKR.
MATERIALS AND METHODS
After informed consent and with institutional approval, 123 ASA physical status I or II patients scheduled for elective unilateral TKR under spinal anesthesia (SA) were enrolled, and those patients who received the surgery in the morning were included in this study. Patients were excluded if they met any of the following criteria: contraindications to regional anesthetic technique (e.g., local infection, sepsis, coagulation abnormality), allergy to local anesthetic and/or opioid, pre-existing neurological deficit in the lower extremity, or inability to comprehend pain scales or to use a PCA device. After surgery in the postanesthesia care unit (PACU), all patients were given an explanation of visual analog scale (VAS) and were familiarized with the use of PCA connected to the femoral catheter. No significant differences were found among the groups in terms of age, gender distribution, weight, height, anesthetic time, and operating time (Table 1) .
We designed this prospective study to evaluate the analgesic Treatment for pruritus consisted of IM chlorpheniramine 4 mg, and treatment in all cases was initiated at the patient's request.
Naloxone was reserved for treatment of pruritus that was resistant to chlorpheniramine therapy. Supplemental analgesia, antiemetic and antipruritic medications, and side effects were recorded for each group at each measuring interval.
The presence and severity of nausea was assessed by using an ordinal scale (0 = no nausea; 1 = mild; 2 = moderate; 3 = severe).
All patients in this series were monitored for respiratory depression by assessment of their respiratory rate, which is the means routinely used to monitor patients after IT morphine in our institution. Respiratory rates were assessed by the study anesthesiologist at the measurement times and also by the ward nurses every four hours. Respiratory frequency was measured with the patients at rest and undisturbed, and prior to making the remaining observations. The incidence of respiratory depression, defined as respiratory rate ＜10 breaths/min, was recorded. Supplemental oxygen was not placed routinely;
however, if at any time their respiratory rate was ＜10 breaths/min, oxygen 3 L/min via nasal cannula was added.
Intravenous naloxone in 0.1 mg increments was to be given for treatment of respiratory depression.
Sedation was scored according to the following scale: 0 = alert; 1 = drowsy; 2 = sleeping, easy to arouse; and 3 = sleeping, difficult to arouse. Significant sedation was defined as a sedation score of 3. Urinary retention could not be assessed VAS pain scores at rest. The VAS scores at rest were significantly lower in all IT morphine groups than control at 6 PM on the day of operation and at 9 AM on POD 1, respectively; however, there were no significant differences among treatment groups. VAS: visual analog scale, PACU: postanesthesia care unit, POD: postoperative day. 
RESULTS
A total of 123 patients were entered into the study. Of these patients, 23 were excluded from the data analysis: femoral nerve block failed despite successful identification of the femoral nerve with a nerve stimulator in six; in 13 patients who had successful initial 3-in-1 block after injection of 0.25% bupivacaine 20 ml, the sensory block disappeared in the ward despite continuous infusion of 0.125% bupivacaine; femoral catheter was accidentally dislodged by patients on POD 1 in three; recording of bolus use of 0.125% bupivacaine was incomplete on POD 2 in one. If a patient was removed from the trial, the same trial was subsequently performed in another patient. The final total of 100 patients were equally distributed among the groups.
The four treatment groups that received IT morphine produced decreased cumulative PCA bolus use of 0.125% bupivacaine for the first two days compared with control (P ＜ 0.05) (Fig. 1) . However, there were no significant differences among any of the treatment groups.
The VAS pain scores at rest were significantly lower in treatment groups than control at 6 PM on the day of operation and at 9 AM on POD 1, respectively (P ＜ 0.05); however, there were no significant differences among treatment groups (Fig. 2) . Pain scores on movement were significantly lower in 0.05, 0.15, and 0.2 mg IT morphine groups than control at 6 PM on the day of operation, respectively (P ＜ 0.05); however, there were no significant differences among treatment groups (Fig. 3) . Pain scores on movement in 0.1 mg IT morphine were also lower than control at 6 PM on the day of operation, but this difference did not reach statistical significance. By contrast, at 6 PM on POD 2, pain scores on movement were 3 . VAS pain scores on movement. The VAS scores on movement were significantly lower in 0.05, 0.15, and 0.2 mg IT morphine than control at 6 PM on the day of operation, respectively; however, there were no significant differences among treatment groups. The VAS scores on movement were significantly higher in 0.05 and 0.1 mg IT morphine than control at 6 PM on POD 2, respectively; however, there were no significant differences among treatment groups. VAS: visual analog scale, PACU: postanesthesia care unit, POD: postoperative day. significantly higher in 0.05 and 0.1 mg IT morphine groups than control, respectively (P ＜ 0.05); however, there were no significant differences among treatment groups (Fig. 3) .
The incidence of nausea was significantly more frequent in 0.15 mg IT morphine than control (P ＜ 0.05) ( Table 2 ). The incidence of vomiting was significantly more frequent in 0.1, 0.15, and 0.2 mg IT morphine groups than control (P ＜ 0.05); however, there were no significant differences among treatment groups ( Table 2 ).
The incidence of pruritus was significantly more frequent in treatment groups than control (P ＜ 0.05); however, there were no significant differences among treatment groups (Table 2 ).
For the rate of administration of antipruritic medication, there were significant differences between control and treatment groups (P ＜ 0.05). Although no significant difference among treatment groups was observed regarding the rate of antipruritic therapy, a significant trend towards an increasing number of patients who required antipruritic therapy was found as IT morphine dose increased (P ＜ 0.05) ( Table 2 A multimodal approach to pain control with the use of a combination of drugs or a multiple analgesic method that relieve pain by different mechanisms has been widely proposed in the literature [19] . Whereas the main site of action of subarachnoid morphine is the opioid receptors in the substantia gelatinosa of the dorsal horn of the spinal cord [20] , femoral nerve block has peripheral effects, as it blocks the massive afferent nociceptive input [5] . After knee surgery, postoperative pain can be associated with reflex spasm of the quadriceps muscle, causing further pain and impaired muscle function.
Abolition of quadriceps muscle spasm by femoral nerve block contributes to the effectiveness of the technique [4] .
IT morphine is effective for acute postoperative pain control in patients undergoing a number of different types of surgery.
In an earlier study, Jacobson et al [14] demonstrated that low dose (0.3 mg) was not effective, but larger doses (1.0 and 2.5 mg) provided reliable and prolonged analgesia in patients undergoing total knee or hip replacement. However, respiratory depression or apnea was common after the administration of larger doses. Thus, doses of IT morphine should be as small as possible to reduce the side-effects. Kalso [21] found that small doses of IT morphine (0.2 mg) were not as effective as larger doses (0.4 mg) in providing prolonged postoperative analgesia after orthopedic surgery. Likewise, Tarkkila et al [11] found that 0.3 mg IT morphine alone was insufficient for the treatment of severe pain after major knee surgery (TKR or open ligament surgery). Magnitude and duration of analgesia after IT morphine were dose-related and increases in PaCO2 were also significantly related to IT morphine dose [16] .
Indeed, it appears that the efficacy of doses above 0.3 mg IT morphine is often limited by side effects [22] . Accordingly, [23] reported that the analgesic effect of 0.1 mg was seen to be greater than that of 0.05 mg and similar to that of 0.2 mg of IT morphine, indicating that 0.1 mg is very likely the minimum effective dose for caesarean section. Accordingly, the optimal doses of IT morphine in the major arthroplasty surgery and caesarean section have been shown to be 0.1 or 0.2 mg [2, 12, 13, 23] . However, in our study the minimum effective dose of IT morphine was as low as 0.05 mg. A possible explanation for the different results may be as follows:
first, in our study, a significant analgesia might have been achieved in part with the 3-in-1 block and therefore any meaningful comparisons could not be obtained in the VAS pain scores among treatment groups; second, the dose range of IT morphine from 0.05 to 0.2 mg used was probably too small to allow any meaningful comparisons for the VAS pain scores.
Pain assessment should be made for patients both at rest and during activity. Because activity is often an important part of the rehabilitation of the surgical patient, it is critical that one assess movement pain [24] . Pain scores with mobilization may provide additional useful information. First, in our study, no difference was noted among treatment groups in VAS scores at rest at 6 PM on POD 2, whereas VAS scores on movement were significantly higher in 0.05 and 0.1 mg IT morphine than control at the same measurement time, Second, in our study, there may be a trend toward decreasing VAS scores at rest and on movement over time in control, whereas a trend toward increasing VAS scores on movement over time in treatment groups. In the postoperative period, hyperalgesia can occur either due to nervous system sensitization by surgical stimuli (nociception-induced hyperalgesia) or to an effect of drugs used (drug-induced hyperalgesia), particularly analgesics such as μ-opioid agonists [26] . Even a single opioid administration induces a short-lasting analgesic effect followed by a delayed anti-analgesic or hyperalgesic effect [27] .
Therefore, it seems that drug-induced hyperalgesia by IT morphine used may lead to a trend toward increasing VAS scores on movement over time in treatment groups in our study.
The emesis is one of the more distressing adverse effects of IT morphine. In our study, there was a significant difference in the incidence of nausea only between 0.15 mg IT morphine and control. The incidence of vomiting was significantly more frequent with 0.1, 0.15, and 0.2 mg IT morphine than control, however, there was no evidence of a difference among treatment groups. This could be explained by the fact that this dosage range might be too small to allow any meaningful comparisons, and routine postoperative antiemetic medications might influence the results. Slappendel et al [12] demonstrated that PONV showed similar overall incidences in all IT morphine groups (0.025−0.2 mg) and that PONV was not induced by these small doses of IT morphine. Similar findings were observed by Murphy et al [13] , who showed no significant difference in the incidence or severity of PONV in the groups that received IT morphine (0.05−0.2 mg) compared with the control.
Pruritus may contribute to patient discomfort. In our study, no difference in the incidence of pruritus among treatment groups was noted. However, a significant trend towards an increasing number of patients who required antipruritic therapy was found as IT morphine dose increased. The need for antipruritic therapy is an index of the severity of the pruritus [13] . Accordingly, we found that the incidence of itching was not dose related, but dose related in the severity of pruritus. To examine our data, there may be a trend toward increasing the duration of pruritus as IT morphine dose increased (data not shown). Similar findings was noted by Kuipers et al [28] who showed the longer duration of pruritus with 0.3 mg (maximum 22 h) versus 0.1 mg IT morphine (maximum 15 h). Meanwhile, Slappendel et al [12] found that the incidence of itching was dose related, as was the incidence of request for antipruritic medication in the dose range of 0.025−0.2 mg of IT morphine. Murphy et al [13] also reported that the overall incidence of pruritus and request for antipruritic therapy was significantly increased in patients who received 0.2 mg IT morphine compared with 0.05 and 0.1 mg IT morphine groups.
The incidence of sedation score of 1 was significantly more frequent with treatment groups than control in our study. To examine our data, none of patients showed a sedation score of 2 or 3, therefore there was no evidence of deep sedation at any of the doses of IT morphine studied. Likewise, Murphy et al [13] found that sedation did not appear to be a problem at the doses of IT morphine (0.05−0.2 mg) used in their study.
Delayed respiratory depression is the most feared side effect of IT morphine and has restricted its use as an usual component of postoperative analgesia. Although the respiratory rate did not reliably indicate hypoxemia [16] , there was no patient with a respiratory rate ＜10 breaths/min in our study. The most reliable clinical sign of significant respiratory depression appears to be a depressed level of consciousness [29] . No patient showed a sedation score of 2 or 3; thus, a significant sedation was not found in all patients given IT morphine in our study. Therefore, it can be assumed that there was no patient with significant respiratory depression and who required oxygen therapy in our study.
Clinicians continue to hesitate to prescribe IT morphine be-cause of the serious nature of opioid-induced respiratory depression. The safest course, therefore, would seem to be to give the minmum effective dose hoping to minimize the possibility of respiratory depression. Although close surveillance of breathing is mandatory there is increasing recognition that low dose neuraxial administration does not obligate patients to be observed in an intense monitoring environment. Glass [15] Finally, after this IT morphine dose, there seems to be no need for particular supervision.
Age seems to be involved in the development of the respiratory depression after IT morphine [18] . The patients in our study had a mean age of 67.4 year. Only nine of the patients were less than 60 years of age. Likewise, the patients in previous studies had a mean age of 65−67 year in major knee surgery [2, 10, 11] . Accordingly, we recommend that lower doses of opiates be used in patients undergoing TKR. In our study, the minimum effective dose of IT morphine was 0.05 mg, and therefore respiratory depression is less likely to occur when such a very low dose of IT morphine is given, even in elderly patients.
Our study has several limitations. First, Slappendel et al [12] has examined doses as small as 0.025 mg IT morphine. Our work did not include patients who received doses smaller than 0.05 mg IT morphine. Therefore, we can not show any minimum dose rather than 0.05 mg IT morphine. Second, Bailey et al [16] found that respiratory rate is not reliable as an indicator of significant respiratory depression after IT morphine and only pulse oximetry reliably detected inadequate In conclusion, our study has shown that IT morphine from 0.05 to 0.2 mg provided comparable and effective postoperative analgesia when combined with continuous 3-in-1 block after TKR. However, the incidence of vomiting was significantly more frequent with 0.1−0.2 mg IT morphine groups compared with control, and there was a significant trend towards an increasing number of patients who required antipruritic therapy as IT morphine dose increased. Therefore, 0.05 mg IT morphine would appear to provide the optimal balance between pain relief and adverse effects following TKR.
